Data Released to the Investors of Dendreon A Head of the AUA Meeting

Prior to the AUA meeting Dendreon released the following to its investors. We will now wait to see what transpires at the AUA meeting which is scheduled to be held in one and a half hours from my posting this. Joel T Nowak MA, MSW – Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival [...]

Waiting On the Side Line with Crossed Fingures and A Prayer

I don't know about you, but I am waiting very anxiously for today's presentation at the AUA conference from Dendreon about Provenge. It is an absolute shame that we have been put into the position that we needed to wait for more men to die before moving ahead. I am concerned that all of the [...]

Dendreon Announces Data Presentations and Webcast on their Experimental Immunotherapy Provenge

Press Release: Dendreon Corporation (Nasdaq: DNDN) announced the following data presentations taking place at the American Urological Association's (AUA) Annual Meeting in Chicago, as well as a Dendreon-sponsored IMPACT data webcast conference call: (for those of us who will be unable to attend the session at AUA in Chicago) April 28, 2009, 2:20 p.m. CDT-"A [...]

About Provenge

As a follow up to yesterday's news about the positive results announced about Provenge, I have received a number of private emails asking questions about the treatment. I hope that the following will answer many of the questions people might still have about Provenge. • The other name for Provenge is sipuleucel-T. • Provenge is [...]

PROVENGE Significantly Prolongs Survival in Men with Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study

What great news has greeted us today. We can now hope that the FDA will quickly approve Provenge and we can get this sorely needed treatment ASAP. If Provenge gets approval from the FDA it will be the first cancer vaccine ever approved. Sadly it will be only the second approved treatment for prostate cancer! [...]

Go to Top